Boehringer Ingelheim and Isis combine cell adhesion programs in $100 mil. agreement.
Executive Summary
BOEHRINGER INGELHEIM AND ISIS COMBINE CELL ADHESION PROGRAMS WORTH $100 MIL. to the antisense firm in a letter of intent agreement. The collaboration, announced March 1, would combine Boehringer Ingelheim and Isis' clinical and research programs aimed at developing cell-adhesion targeted drugs. The cell adhesion alliance is subject to a definitive agreement that the companies say is expected to close in the second quarter. B-I's financial advisor for the transaction is Vector Securities.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth